Pharma Focus Asia
KP - Sustainable Packaging Solutions

Advanced Accelerator Applications Plans to Build Second US Manufacturing Site in Indianapolis


Advanced Accelerator Applications plans to build a new manufacturing facility for currently approved therapy and pipeline drug candidates in Indianapolis. The expansion would be the second US manufacturing site for targeted radioLigand therapy.


The new manufacturing facility designed with an area covering 50,000 square feet will produce targeted radioligand drugs which are used in the treatment of cancer.

The new facilities will include advanced manufacturing technologies; following the latest innovations in radiopharmaceutical production. The production facility is intended to be built with highest quality standards of safe and efficient operations. New construction is intended to support near and long-term manufacturing capacity planning for AAA’s marketed products and for clinical supply.

The new manufacturing facility is expected to complete the construction and start its initial operations by 2023.


NameAdvanced Accelerator Applications
TypeNew Facility
Latest Issue
Get instant
access to our latest e-book
Standard BioTools™MFA + MMA 2024CPHI Chine || PMEC China 2024Gibco Adherent Kidney Media PanelAsia Healthcare Week 2024CPHI Korea 2024Equinix accelerated medical research...CHEMICAL INDONESIA 2024Thermofisher - Antibody Therapeutic PolishingINALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024ISPE Singapore Affiliate Conference & Exhibition 2024Rehab Expo 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024
Searching for an end-to-end patient tech solution?